Skip to content Skip to footer
Subscribe Now
NEWS

Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Programs to Primevera Therapeutics in a ~$584.5M Deal

Shots: Foresee has entered into an exclusive global licensing agreement with Primevera for its MMP-12 inhibitor programs, which incl. FP-025, FP-020 & third-generation MMP-12 inhibitors in discovery stage As per the deal, Foresee USA will receive a $10M upfront, ~$574.5M in milestones, & tiered single-digit royalties, or alternatively a tiered share of sublicense proceeds in lieu…
January 8, 2026

Read more

NEWS

Cartography Biosciences and Pfizer Forge ~$865M Deal for Discovery of Tumor-Selective Antigens

Shots: Cartography has entered into a strategic collaboration with Pfizer to discover tumor-selective antigens, leveraging Cartography’s ATLAS & SUMMIT platforms Under a multi-year deal, Cartography will discover & validate tumor-selective antigens in an undisclosed cancer, with Pfizer holding opt-in rights for research, development & commercialization; Cartography retains full ownership of its lead asset CBI-1214 Cartography…
January 7, 2026

Read more

NEWS

Nimbus Therapeutics and Eli Lilly Enter ~$1.3B Deal to Develop Oral Metabolic Therapies

Shots: Nimbus has entered into a multi-year research collaboration & exclusive, worldwide license agreement with Eli Lilly to develop a novel oral treatment for obesity & other metabolic diseases Building on their prior AMPK cardiometabolic collaboration, Nimbus & Lilly have entered into a new partnership applying Nimbus’ computational chemistry & structure-based design to an…
January 7, 2026

Read more

NEWS

Earendil Labs and Sanofi Forge ~$2.56B Deal to Advance Bispecific Antibodies for Autoimmune Diseases

Shots: Earendil Labs has entered into a strategic collaboration with Sanofi to advance bispecific candidates for autoimmune & inflammatory diseases using Earendil's discovery platform Under the deal, Earendil Labs will identify & optimize bispecific antibody candidates for autoimmune & inflammatory disease targets, while Sanofi will handle the development & worldwide commercialization of the products As…
January 5, 2026

Read more

NEWS

Insilico Medicine and Servier Enter ~$888M R&D Alliance to Advance Novel Oncology Therapies

Shots: Insilico Medicine has entered into a multi-year R&D collaboration with Servier to identify & develop novel oncology therapeutics for challenging targets using Insilico's Pharma.AI As per the deal, Servier will share R&D costs &, upon successful identification of potential candidates, assume responsibility for clinical validation, regulatory engagement, & global commercialization of the resulting oncology drug candidates…
January 5, 2026

Read more

NEWS

BioAtla and GATC Health Announce $40M SPV Transaction to Advance Ozuriftamab Vedotin into P-III Study for 2L+ OPSCC

Shots: BioAtla and GATC Health announce  into a $40M special purpose vehicle (SPV) transaction to advance ozuriftamab vedotin (Oz-V), a CAB-ROR2-ADC, into a registrational P-III study for 2L+ oropharyngeal squamous cell carcinoma (OPSCC) Under the agreement, BioAtla will receive $5M upfront to support operations and P-III study execution, with the remaining $35M expected to close…
January 2, 2026

Read more

NEWS

Intelligent Bio Solutions and Syrma Johari MedTech Collaborate to Advance Global Production Capability and Margin Expansion

Shots: Intelligent Bio Solutions has entered into a strategic manufacturing partnership with Syrma Johari MedTech to scale production of its Intelligent Fingerprinting Drug Screening Reader and support long-term margin improvement Under the agreement, the partnership advances INBS’ global manufacturing strategy by diversifying suppliers, strengthening supply chain resilience, expanding capacity, and increasing flexibility ahead of anticipated multi-region…
January 2, 2026

Read more

NEWS

Transcenta and EirGenix Collaborate to Advance Integrated Continuous Biomanufacturing Technologies

Shots: EirGenix has entered into a strategic collaboration and non-exclusive licensing agreement with Transcenta for its Highly Intensified Continuous Bioprocessing (HiCB) platform Under the agreement, Transcenta will grant EirGenix a non-exclusive license to its HiCB platform, incl. continuous perfusion & integrated hybrid continuous purification process technologies, as well as documentation, know-how & regulatory support to…
December 29, 2025

Read more

NEWS

Harbour BioMed Collaborates with Yantai Lannacheng Biotechnology to Develop Radionuclide Drug Conjugates (RDCs)

Shots: Harbour BioMed has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology to jointly advance the development of next-generation RDCs Collaboration will combine Harbour’s fully human antibody discovery capabilities via its Harbour Mice platform with Lannacheng’s radiopharmaceutical R&D & commercialization strengths Harbour Mice platform provides fully human mAbs in both conventional & heavy chain-only…
December 29, 2025

Read more

Load more